2025 China Asthma And Copd Drug Market Revenue Opportunities Report
Description
The 2025 China Asthma And Copd Drug Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Asthma and COPD Drug Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the asthma and COPD drug market in China are Sanofi, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., and Pfizer Inc. Sanofi is advancing its respiratory pipeline with innovative asthma and COPD drugs such as amlitelimab and Dupixent, the latter recently approved in China for COPD treatment targeting eosinophilic phenotype patients. Teva and Merck also hold significant market shares globally and are focused on pharmaceutical developments for respiratory diseases, including asthma and COPD. Pfizer is a key player contributing to market growth through advanced therapies and increased awareness.
Verona Pharma represents a specialized leader in COPD treatment with its dual PDE3/PDE4 inhibitor drug, Ohtuvayre (ensifentrine), which has FDA approval and aims to improve lung function and reduce flare-ups. The COPD and asthma market in China is growing rapidly due to increasing disease prevalence—about 100 million affected by COPD alone—rising smoking rates, government screening programs, and expanding healthcare infrastructure. These companies leverage innovation, strategic partnerships, and clinical advancements to address China's significant respiratory disease burden.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Asthma and COPD Drug Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the asthma and COPD drug market in China are Sanofi, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., and Pfizer Inc. Sanofi is advancing its respiratory pipeline with innovative asthma and COPD drugs such as amlitelimab and Dupixent, the latter recently approved in China for COPD treatment targeting eosinophilic phenotype patients. Teva and Merck also hold significant market shares globally and are focused on pharmaceutical developments for respiratory diseases, including asthma and COPD. Pfizer is a key player contributing to market growth through advanced therapies and increased awareness.
Verona Pharma represents a specialized leader in COPD treatment with its dual PDE3/PDE4 inhibitor drug, Ohtuvayre (ensifentrine), which has FDA approval and aims to improve lung function and reduce flare-ups. The COPD and asthma market in China is growing rapidly due to increasing disease prevalence—about 100 million affected by COPD alone—rising smoking rates, government screening programs, and expanding healthcare infrastructure. These companies leverage innovation, strategic partnerships, and clinical advancements to address China's significant respiratory disease burden.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
